Prime Medicine, Inc. (PRME)
NASDAQ: PRME · Real-Time Price · USD
1.875
-0.115 (-5.78%)
Mar 31, 2025, 1:27 PM EDT - Market open
Prime Medicine Employees
Prime Medicine had 214 employees as of December 31, 2024. The number of employees decreased by 20 or -8.55% compared to the previous year.
Employees
214
Change (1Y)
-20
Growth (1Y)
-8.55%
Revenue / Employee
$13,939
Profits / Employee
-$915,336
Market Cap
239.37M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 214 | -20 | -8.55% |
| Dec 31, 2023 | 234 | 59 | 33.71% |
| Dec 31, 2022 | 175 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PRME News
- 13 days ago - Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) - GlobeNewsWire
- 4 weeks ago - Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 5 weeks ago - Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference - GlobeNewsWire
- 2 months ago - Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm - PRNewsWire
- 4 months ago - Prime Medicine's Bristol Myers Partnership Boosts Outlook For Gene Editing Therapies - Seeking Alpha
- 4 months ago - Wilson Disease Pipeline Market Research Report 2024: Comprehensive Insights on 5+ Drugs Featuring Vivet Therapeutics, Depymed, Prime Medicine, and Deep Genomics - GlobeNewsWire
- 5 months ago - Prime Medicine to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 5 months ago - Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson's Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress - GlobeNewsWire